What Is Non-Radiographic Axial Spondyloarthritis?

Non-radiographic axial spondyloarthritis (nr-axSpA) is a chronic inflammatory disease that primarily affects the sacroiliac joints and spine but does not show the structural damage visible on standard X-rays that defines its better-known relative, ankylosing spondylitis. It belongs to the same disease family and produces similar symptoms, including persistent inflammatory back pain, stiffness, and fatigue. The condition was formally recognized as a distinct classification category only in 2009, and much of the clinical and research landscape is still catching up to what that recognition means for diagnosis, treatment, and long-term outlook.

Where Nr-axSpA Fits in the Spondyloarthritis Spectrum

Axial spondyloarthritis (axSpA) is now understood as a single disease with two forms. The radiographic form is ankylosing spondylitis (AS), identified when X-rays show definitive structural damage to the sacroiliac joints. The non-radiographic form, nr-axSpA, is identified when a person has the hallmark symptoms and either shows active inflammation on MRI or meets a combination of clinical features including the genetic marker HLA-B27.

The Assessment of Spondyloarthritis International Society (ASAS) classification criteria, introduced in 2009, formalized this distinction. Before those criteria, the only widely accepted classification for axial disease was the modified New York criteria for AS, which required visible X-ray damage. That meant people in the earlier or less structurally destructive phase of the disease had no formal classification at all, even when their symptoms and inflammatory burden were substantial.¹ The ASAS criteria have two “arms” for classification: an imaging arm (sacroiliitis on MRI or X-ray plus at least one other SpA feature) and a clinical arm (HLA-B27 positive plus at least two other SpA features). These arms perform differently in validation studies and carry different implications for disease trajectory, which has generated ongoing debate about whether they capture the same underlying population.²

What It Feels Like

The defining symptom is inflammatory back pain, which behaves quite differently from the mechanical back pain most people experience at some point in life. Inflammatory back pain tends to start before age 40, comes on gradually rather than suddenly, improves with movement and exercise but worsens with prolonged rest, and often disturbs sleep in the second half of the night. Morning stiffness lasting more than 30 minutes is common.

Beyond the spine, nr-axSpA frequently involves other parts of the body. A meta-analysis comparing nr-axSpA and AS found that peripheral arthritis affected roughly 28% of nr-axSpA patients, enthesitis (painful inflammation where tendons attach to bone) affected about 35%, and dactylitis (swollen “sausage” fingers or toes) appeared in about 6%. Psoriasis and inflammatory bowel disease each appeared in about one in ten patients. The one clear difference was uveitis, an inflammatory eye condition, which was more common in AS (about 23%) than in nr-axSpA (about 16%).³ Fatigue is another major complaint and can be severe enough to interfere with work and daily life, especially in patients whose disease activity remains high.⁴

Why It Takes So Long to Get Diagnosed

One of the most frustrating aspects of nr-axSpA is the diagnostic delay. Because there is no single definitive test, and because X-rays look normal by definition, many patients spend years bouncing between primary care physicians, orthopedists, and physiotherapists before seeing a rheumatologist. Research into the patient journey shows that health professionals outside rheumatology often struggle to recognize nr-axSpA, leading to multiple detours and substantial delays that directly affect patients’ wellbeing.⁵

Standard blood tests are not much help in the early stages. A study of the SpondyloArthritis Caught Early (SPACE) cohort found that CRP and ESR levels were not significantly different between patients who met the ASAS criteria for axSpA and those who did not.⁶ In other words, your blood work can come back looking perfectly normal while your sacroiliac joints are actively inflamed. Later in the disease course, inflammatory markers become more useful for tracking activity and guiding treatment decisions, but as an early diagnostic tool, they often miss the mark.

MRI of the sacroiliac joints is the key imaging tool. In one study of nr-axSpA patients, about three-quarters showed active sacroiliitis on MRI.⁷ Emerging techniques like multi-habitat radiomics, which quantify spatial patterns of bone marrow edema on MRI, are showing promise for detecting early active sacroiliitis more objectively than standard visual reads by radiologists.⁸ But for now, the practical reality is that diagnosis depends on a rheumatologist putting together a pattern of symptoms, HLA-B27 status, imaging findings, and clinical judgment.

The Role of HLA-B27

Roughly 60% to 90% of axSpA patients worldwide carry the HLA-B27 gene, depending on the population studied.⁹ Testing positive for HLA-B27 is one of the most useful clues a doctor has when evaluating chronic back pain in a young adult, but it is far from the whole picture. Most people who carry HLA-B27 never develop axSpA. And a meaningful minority of people with confirmed nr-axSpA are HLA-B27 negative. The proportion of HLA-B27-negative patients tends to be higher among non-White populations and among those with nr-axSpA specifically, which creates an additional diagnostic hurdle for these groups.¹⁰ If you are HLA-B27 negative, clinicians may be slower to consider axSpA, and the path to diagnosis can stretch even longer.

Gender Differences That Affect Diagnosis and Treatment

Nr-axSpA does not affect men and women identically, and the differences matter for how the disease gets recognized and managed. Women with nr-axSpA experience longer diagnostic delays, higher levels of perceived disease activity, and more enthesitis compared with men. They are also less likely to be HLA-B27 positive, which may partly explain why diagnosis takes longer.¹¹

A separate study found that female patients had significantly higher enthesitis scores and higher self-reported disease activity compared with males, while measures of spinal mobility and physical function did not differ significantly between the groups.¹² Women also tended to have more peripheral arthritis and longer disease duration before diagnosis. Perhaps most concerning is the treatment gap: in one real-world cohort, only 17% of women achieved a major clinical response to biologic therapy compared with 38% of men, a difference that held up even after adjusting for other factors.¹³ Researchers have not fully sorted out why this happens, but it likely reflects a combination of biological differences in disease expression, different patterns of inflammation, and possibly diagnostic misclassification.

Does Nr-axSpA Always Progress to Ankylosing Spondylitis?

One of the most common questions people with nr-axSpA have is whether their condition will eventually “become” AS. The answer is that most do not progress, at least not within the time frames researchers have studied. A population-based cohort that followed 83 patients with new-onset nr-axSpA over roughly a decade found that the probability of remaining in the non-radiographic stage was about 94% at five years, 83% at ten years, and 74% at fifteen years. Only about a quarter of patients had progressed to AS by the end of follow-up.¹⁴

Progression rates across the broader literature range from about 10% to 40% over two to ten years, depending on the study population and follow-up length.¹⁵ Patients classified through the imaging arm of the ASAS criteria (those with MRI-confirmed sacroiliitis) progressed more frequently and more quickly than those classified through the clinical arm. In the population-based study, the imaging-arm group progressed at about 28% compared with 17% in the clinical arm.¹⁶ The researchers interpreted this as suggesting either that many nr-axSpA patients truly have a condition unlikely to produce structural damage, or that nr-axSpA represents a very long prodromal phase where detectable X-ray changes can take decades to appear.

Risk factors that increase the likelihood of progression include elevated CRP, active sacroiliitis on MRI, smoking, male sex, and HLA-B27 positivity. But predicting which individual patient will progress remains unreliable, which is one reason ongoing monitoring matters.

Treatment Approaches

The first-line treatment for nr-axSpA is the combination of non-steroidal anti-inflammatory drugs (NSAIDs) and physiotherapy.¹⁷ NSAIDs work similarly well in nr-axSpA and AS for symptom control, and there is evidence they reduce inflammatory changes visible on MRI, though uncertainty remains about the best long-term dosing strategy.¹⁸ Unlike in rheumatoid arthritis, conventional disease-modifying drugs like methotrexate and sulfasalazine have no proven benefit for the axial symptoms of nr-axSpA, though they may help peripheral joint involvement.

Physical therapy and structured exercise are not just add-ons; they remain important regardless of what medications a person takes. Even in the era of biologic drugs, unmet needs persist for patients who do not respond to or cannot tolerate medication, making exercise programs, stretching, and posture work essential parts of long-term management.¹⁹

When NSAIDs are not enough, TNF inhibitors (such as adalimumab, certolizumab, and etanercept) are the most established biologic option. A meta-analysis found that TNF blockers produce clinically meaningful improvements in disease activity and physical function for nr-axSpA patients, though the effect sizes are somewhat smaller than those seen in AS.²⁰ A systematic review and economic evaluation reached a similar conclusion, confirming clinical benefit while noting the difference in magnitude between the two disease forms.²¹ Achieving a strong clinical response translates into meaningful gains in physical function, quality of life, and work productivity.²²

IL-17 inhibitors (such as secukinumab and ixekizumab) are now also approved for nr-axSpA and represent another option for patients who fail TNF inhibitors. Janus kinase (JAK) inhibitors have entered the picture as well, adding an oral alternative to injectable biologics. Interestingly, despite strong theoretical reasons to expect that blocking IL-23 would help axSpA, two major clinical trials of anti-IL-23 antibodies showed no benefit. This was a surprise because the IL-23 and IL-17 pathways were thought to be tightly linked, and IL-17 inhibitors clearly work. The negative IL-23 results suggest that these two signaling pathways are at least partly independent in spinal inflammation, which has reshaped how researchers think about the disease’s underlying biology.²³

Measuring Disease Activity

Two main tools are used to track how active nr-axSpA is over time. The BASDAI is a patient-reported questionnaire covering fatigue, spinal pain, joint pain, enthesitis, and morning stiffness. The ASDAS incorporates some of the same patient-reported items but adds a blood inflammatory marker (usually CRP), giving a composite score that blends subjective experience with objective lab data. Both instruments perform similarly well in nr-axSpA and AS, and the ASDAS cutoff values that separate low from high disease activity are essentially the same for both disease forms.²⁴ This is reassuring because it means the same monitoring framework works across the whole axSpA spectrum.

There is a practical wrinkle, though. While these scores are effective for tracking changes over time and gauging treatment response, the inflammatory markers that feed into the ASDAS (CRP and ESR) have low sensitivity for identifying nr-axSpA in the first place. A recent comparative study found that both markers are highly specific for very high disease activity in certain scenarios, particularly in patients not yet on biologic therapy, but their overall sensitivity remains limited.²⁵ So these blood tests are more useful for monitoring a known disease than for catching it early.

The Gut Connection

The overlap between nr-axSpA and inflammatory bowel disease is more than just a clinical coincidence. Research into the gut microbiome has found that dysbiosis, an imbalance in gut bacterial communities, is more frequent in axSpA patients than in healthy controls. A study that examined this relationship found gut dysbiosis was associated with worse disease activity and poorer physical function, and this association held regardless of whether the patient had overt gut inflammation or was taking biologic treatment.²⁶ The mechanisms connecting the gut and the joints are still being worked out, but microscopic gut inflammation has been found in a substantial proportion of axSpA patients who have no digestive symptoms at all. This suggests the gut-joint axis is not limited to people with diagnosed inflammatory bowel disease but may be a broader feature of the disease.

Living With an Invisible Condition

Because there is nothing to see on X-ray and blood tests may come back normal, nr-axSpA is often called an “invisible” disease. This invisibility creates real problems beyond just diagnostic delay. Patients frequently report that family members, employers, and even some doctors do not take their symptoms seriously. The disconnect between how a person feels and what their tests show can be genuinely demoralizing.

The disease burden is not trivial. Higher disease activity at two years was linked to less improvement in back pain and significantly worse fatigue scores over time, reinforcing the importance of getting disease activity under control early.²⁷ People whose disease is well controlled report substantially better physical function, quality of life, and work productivity than those with persistent high activity.²⁸ The gap between controlled and uncontrolled disease is wide enough that effective treatment changes not just symptom scores but participation in daily life and the ability to hold down a job.

This is one reason the “non-radiographic” label can be misleading. Some patients, hearing that their X-rays are clear, assume their condition is mild or preliminary. It is not. Nr-axSpA is a real disease with real inflammatory activity, real pain, and real consequences for quality of life. The “non-radiographic” part describes what the imaging shows, not how serious the condition is. A person with nr-axSpA and high disease activity can be more impaired in daily life than someone with structural X-ray changes who is in remission on treatment.